Medication Mishap
Severe prolonged hypophosphataemia following iron infusion
- Aust Prescr 2026;49:248-51
- 1 December 2026
- DOI: 10.18773/austprescr.2026.051

A 26-year-old man was identified with severe hypophosphataemia (serum phosphate less than 0.3 mmol/L; reference range 0.70–1.50 mmol/L) on routine pathology prior to an intravenous immunoglobulin infusion. Symptoms included new-onset malaise and fatigue. Other pathology results included calcium corrected for hypoalbuminuria 1.99 mmol/L (2.10–2.60 mmol/L), magnesium 0.75 mmol/L (0.70–1.50 mmol/L) and parathyroid hormone 13.9 pmol/L (2.0–9.0 pmol/L).
Relevant medical history included common variable immunodeficiency, severe Crohn disease with small bowel involvement, chronic norovirus and recent Clostridioides difficile infection, low body weight (body mass index 17.2 kg/m2) and low bone mineral density (age-matched Z-score −3.5).
Fifteen days before the current presentation, the patient had received an intravenous iron polymaltose infusion (1000 mg of iron). Pretreatment pathology results were as follows: haemoglobin 115 g/L (130–180 g/L), ferritin 28 micrograms/L (30–400 micrograms/L), calcium corrected for hypoalbuminaemia 2.31 mmol/L (2.10–2.60 mmol/L), phosphate 1.21 mmol/L (0.70–1.50 mmol/L), 25(OH)-vitamin D 65 nanomol/L (50–150 mmol/L) and estimated glomerular filtration rate >90 mL/min/1.73 m2.
Seven months earlier, an intravenous ferric carboxymaltose infusion (1000 mg of iron) was administered (pretreatment haemoglobin 119 g/L, ferritin 7 micrograms/L), with a subsequent 5-day history of hypophosphataemia (lowest measured concentration less than 0.3 mmol/L) requiring intravenous and oral phosphate supplementation.
The patient’s current medication regimen (Box 1) was significant for sirolimus, an immunosuppressant. Their serum sirolimus concentration was monitored, and was consistent with previous results.
Based on his current presentation, history and pathology data, a presumptive diagnosis of hypophosphataemia secondary to iron infusion was made. A 13-day inpatient admission was required for intravenous phosphate (doses ranging from 10 to 90 mmol per day) and oral phosphate (1.5 g [3 mmol] phosphorus three times daily). Other medications commenced were oral calcitriol 0.75 micrograms twice daily for hypocalcaemia and oral magnesium aspartate 1000 mg (3 mmol) twice daily for hypomagnesaemia (lowest concentration during admission 0.58 mmol/L).
Renal phosphate wasting was confirmed by a low tubular maximum reabsorption of phosphate to glomerular filtration rate (TmP/GFR) ratio (0.28 mmol/L; reference range 0.70–1.35 mmol/L) on day 2 of the admission. The patient’s fibroblast growth factor-23 (FGF-23) concentration was measured on day 7 and was elevated (317 nanograms/L; reference range 23.2–95.4 nanograms/L).
Following discharge, oral therapies were continued for 4 weeks, and intermittent doses of intravenous phosphate replacement were administered at an infusion clinic and during a 3-day readmission. Despite this, phosphate concentrations could not be sustained. The repeated hospitalisation and frequent infusion clinic attendances caused significant psychological distress and disruptions to the patient’s studies.
Fifty-two days after the iron infusion, a single dose of the FGF-23 inhibitor burosumab (20 mg) was administered subcutaneously (an off-label indication, prescribed with local individual patient use approval). Phosphate concentrations were subsequently sustained in the normal range without further supplementation.
Eighteen months later the patient received a ferric derisomaltose infusion (1000 mg of iron) with no adverse effects.
Hypophosphataemia is a recognised adverse effect of intravenous iron and was highlighted in recent Australian and New Zealand safety updates.1,2 It can occur with any intravenous iron preparation, but has been most reported with ferric carboxymaltose.3-5 Onset is approximately 4 to 14 days, and it may persist for 1 to 6 months. Although often self-limiting and asymptomatic, hypophosphataemia may be severe and require hospitalisation. Phosphate is important for bone mineralisation, metabolism, enzyme function and cellular structure. Prolonged hypophosphataemia can lead to osteomalacia.3-6
In an Australian cohort of 2367 patients, the incidence of hypophosphataemia following iron infusion was 43.5%; hypophosphataemia was severe (defined in the study as less than 0.32 mmol/L) in 4.4% of patients and moderate (0.32–0.64 mmol/L) in 32.0%.3 Moderate to severe hypophosphataemia was most common for ferric carboxymaltose and iron polymaltose.3 The lowest incidence of hypophosphataemia has been reported with ferric derisomaltose (less than 5%).4 The mechanism for this variability is unclear but is possibly related to differing physicochemical properties of the iron–carbohydrate complexes, influencing binding to FGF-23.3-5
Iron administration is believed to inhibit the cleavage of FGF-23. A raised concentration of active FGF-23 increases urinary phosphate loss, reduces 25(OH)-vitamin D activation and increases the breakdown of 1,25(OH2)-vitamin D.3-5 Thus, gut absorption of phosphate and calcium is reduced, stimulating parathyroid hormone secretion, which may also be reduced in magnesium deficiency.7 The patient described in this case report had a low TmP/GFR ratio, confirming renal phosphate wasting, and an elevated FGF-23 concentration, supporting the diagnosis of iron-associated hypophosphataemia. Timely FGF-23 measurement is not readily available and does not need to be routinely requested for uncomplicated cases of iron-associated hypophosphataemia; however, it can be useful when the cause of hypophosphataemia is unclear. In contrast, the TmP/GFR ratio is important for assessment of urinary phosphate excretion and to guide differential diagnosis; it can be calculated from paired blood and second-void fasting urine creatinine and phosphate samples using an online calculator.8,9
Risk factors for hypophosphataemia that were present in this patient included malabsorption, low body weight, severe iron deficiency, repeated iron infusions, vitamin D deficiency, raised parathyroid hormone and a low baseline phosphate concentration.3-7 The patient was also taking sirolimus, which is associated with phosphaturia.10
Another important risk factor for hypophosphataemia, which was not present in this patient, is the recent administration of antiresorptive therapies (e.g. denosumab, zoledronic acid).7 These agents may cause hypocalcaemia (although rarely symptomatic if individuals are vitamin D replete), leading to increased parathyroid hormone secretion and urinary phosphate loss.
The management of hypophosphataemia following iron infusion is guided by assessment of the patient’s symptoms, their serum calcium, phosphate, 25(OH)-vitamin D and magnesium concentrations and local guidelines.6 Mild hypophosphataemia (phosphate concentration between 0.61 mmol/L and the lower limit of the laboratory’s reference range) that is asymptomatic may not require treatment, but the patient should be monitored to identify potential deterioration. Moderate hypophosphataemia (0.30–0.60 mmol/L) can be managed with oral phosphate replacement and calcitriol. Severe or refractory phosphate deficiency may require intravenous and oral phosphate, along with calcitriol, correction of other electrolyte abnormalities and specialist advice (Figure 1).3-7
In this patient, to treat refractory hypophosphataemia, reduce further hospitalisation and minimise ongoing distress, off-label burosumab (a high-cost FGF-23 inhibitor) was administered with individual patient approval.6 Although burosumab directly addresses the underlying pathogenesis of FGF-23 excess in iron infusion–associated hypophosphataemia, this is not routine therapy.
Iron infusions are increasingly prescribed and an awareness of the potential for significant hypophosphataemia is important. Local protocols for iron infusion management should be in place. Guidance for administration in primary care settings has been published.11
Careful initial assessment of the need for iron infusion and potential risk factors for hypophosphataemia is necessary.
In patients with risk factors:
In patients without risk factors:
Manage hypophosphataemia based on local guidelines with specialist advice as necessary.6,7
The figure is a flow chart that begins with assessing the patient for risk factors for hypophosphataemia. If there are no risk factors, post-infusion pathology testing is not required, unless the patient develops symptoms consistent with hypophosphataemia. If there are risk factors, serum phosphate, calcium and magnesium concentrations should be measured 1 to 2 weeks after the iron infusion (or earlier if they become symptomatic). If the post-infusion phosphate concentration is below 0.3 mmol/L, or it is below 0.6 mol/L and the patient is symptomatic, the patient requires hospital management with intravenous and oral phosphate plus oral calcitriol. Serum phosphate and calcium should be checked again within 24 hours. If the phosphate concentration is between 0.3 and 0.6 mmol/L without symptoms, or it is between 0.61 mmol/L and the lower limit of the laboratory’s reference range and the patient has symptoms, they can be managed at home with oral phosphate and calcitriol. Serum phosphate and calcium should be checked again in 3 to 4 days. If the phosphate concentration is between 0.61 mmol/L and the lower limit of the laboratory’s reference range without symptoms, no treatment is required but the phosphate and calcium concentration should be rechecked in 7 days.
Patient consent for publication of this case study was obtained by the authors.
Conflicts of interest: Jane Ludington, Stephanie Baddock, Brenda Ta and Michele Arcidiacono declare that they have no conflicts of interest. Angela Sheu has received speaker fees and travel from Eli Lilly.
This article is peer reviewed.
Australian Prescriber welcomes Feedback.
Senior Pharmacist, Department of Diabetes and Endocrinology, St Vincent’s Hospital, Sydney
Senior Pharmacist, Pharmacy Department, St Vincent’s Hospital
Pituitary Fellow, Department of Diabetes and Endocrinology, St Vincent’s Hospital, Sydney
Endocrine Advanced Trainee, Department of Diabetes and Endocrinology, Westmead Hospital, Sydney
Lead Pharmacist, Quality Use of Medicines, Pharmacy Department, St Vincent’s Hospital, Sydney
Endocrinologist, Department of Diabetes and Endocrinology, St Vincent’s Hospital, Sydney
Endocrinologist, Faculty of Medicine and Health, UNSW, Sydney